SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.930
+0.040 (1.03%)
Mar 4, 2026, 4:00 PM EST - Market closed
SAB Biotherapeutics Employees
SAB Biotherapeutics had 63 employees as of December 31, 2024. The number of employees increased by 6 or 10.53% compared to the previous year.
Employees
63
Change (1Y)
6
Growth (1Y)
10.53%
Revenue / Employee
$1,821
Profits / Employee
-$68,064
Market Cap
187.09M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 63 | 6 | 10.53% |
| Dec 31, 2023 | 57 | 1 | 1.79% |
| Dec 31, 2022 | 56 | -83 | -59.71% |
| Mar 31, 2022 | 148 | 62 | 72.09% |
| Dec 31, 2021 | 139 | 53 | 61.63% |
| Sep 30, 2021 | 143 | 57 | 66.28% |
| Jun 30, 2021 | 137 | - | - |
| Dec 31, 2020 | 86 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Molecular Partners AG | 153 |
| Nkarta | 105 |
| Vaxart | 105 |
| Tonix Pharmaceuticals Holding | 81 |
| Compugen | 74 |
| Cartesian Therapeutics | 66 |
| Galectin Therapeutics | 15 |
| Sagimet Biosciences | 14 |
SABS News
- 2 days ago - SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director - GlobeNewsWire
- 2 months ago - SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - First Patient Dosed in SAB BIO's SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D - GlobeNewsWire
- 2 months ago - SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D - GlobeNewsWire
- 3 months ago - SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management - GlobeNewsWire
- 3 months ago - SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 months ago - SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 - GlobeNewsWire